Table 3.
Characteristics of 19-28 studies included in the meta-analysis
| Author (year) | Ethnicity | Cancer type | Sample size | Age | Cutoff (hTERT) | Outcome | HR | 95% CI | NOS score | |
|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||
| Lower | Upper | |||||||||
| Chen C (2014) | Asian | Gliomas (III-IV) | 62 | Mutant versus wildtype | OS | 4.148 | 1.973 | 8.721 | 7 | |
| Astrocytoma (II) | OS | 3.058 | 1.886 | 4.958 | ||||||
| Killela PJ (2014)* | Caucasian | Gliomas (II) | 442 | NA | Mutant/IDH mutant versus wildtype/IDH mutant | OS | 0.93 | 0.37 | 2.37 | 9 |
| Gliomas (III) | Mutant/IDH mutant versus wildtype/IDH mutant | OS | 0.87 | 0.42 | 1.79 | |||||
| Mutant/IDH wildtype versus wildtype/IDH wildtype | OS | 1.39 | 0.27 | 7.16 | ||||||
| Gliomas (IV) | Mutant/IDH wildtype versus wildtype/IDH wildtype | OS | 1.26 | 0.87 | 1.82 | |||||
| Mutant/IDH mutant versus wildtype/IDH mutant | OS | 0.85 | 0.58 | 1.25 | ||||||
| Nonoguchi N (2013) | Caucasian | GBM (IV) | 187 | NA | Mutant (C228T) versus wildtype | OS | 1.50 | 1.07 | 2.11 | 8 |
| Mutant (C250T) versus wildtype | OS | 1.17 | 0.76 | 1.80 | ||||||
| Gandhi P (2021) | Caucasian | Gliomas (II-IV) | 135 | NA | Plasma protein expression (1.309 ng/L) | OS | 1.230 | 1.075 | 1.408 | 7 |
| Elsers D (2021) | Caucasian | GBM (IV) | 53 | Adult | IHC expression score | OS | 0.691 | 0.310 | 1.549 | 7 |
| Potharaju M (2019) | Caucasian | GBM (IV) | 87 | Adult | IRS1-6 versus IRS7-12 | OS | 1.65 | 0.94 | 2.89 | 6 |
| Rute JM (2017) | Caucasian | GBM (IV) | 55 | Adult | Expression | OS | 1.034 | 1.001 | 1.067 | 6 |
| Gandhi P (2017) | Caucasian | Gliomas (II-IV) | 72 | NA | Intra-tumor expression 2.315% | OS | 1.057 | 1.030 | 1.080 | 6 |
| Plasma protein 1.309 ng/L | OS | 1.322 | 1.160 | 1.510 | ||||||
| Dorris K (2014)* | Caucasian | Gliomas (IV) | 20 | Adult | Protein expression | OS | 0.90 | 0.04 | 19.25 | 6 |
| Lötsch D (2013) | Caucasian | GBM (IV) | 100 | All | mRNA expression | OS | 1.02 | 0.61 | 1.71 | 7 |
*Data extracted form survival curve. Data of hTERT promoter mutation (n=22) and hTERT expression difference (n=7) in glioma patients. GBM=Glioblastoma; hTERT=Human telomerase reverse transcriptase; IDH=Iso-citrate dehydrogenase; OS=Overall survival; NA=Not available; CI=Confidence interval; NOS=Newcastle-Ottawa Scale; HR=Hazard ratio; IHC=Immunohistochemistry; IRS=Immunoreactivity score